PA8800401A1 - Productos quimioterapeuticos cristalinos - Google Patents
Productos quimioterapeuticos cristalinosInfo
- Publication number
- PA8800401A1 PA8800401A1 PA20088800401A PA8800401A PA8800401A1 PA 8800401 A1 PA8800401 A1 PA 8800401A1 PA 20088800401 A PA20088800401 A PA 20088800401A PA 8800401 A PA8800401 A PA 8800401A PA 8800401 A1 PA8800401 A1 PA 8800401A1
- Authority
- PA
- Panama
- Prior art keywords
- crystal
- chemotherapeutic products
- chemotherapeutic
- products
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
FORMA CRISTALINA 2 DESOLVATADA DE N-[4-[3-AMINO-1H-INDAZOL-4-IL]FENIL]-N-[2-FLUORO-5-METILFENIL]UREA, MANERAS PARA ELABORARLA, FORMULACIONES QUE COMPRENDEN A LA MISMA Y ELABORADAS CON LA MISMA Y METODOS DE TRATAMIENTOS DE PACIENTES QUE PADECEN UNA ENFERMEDAD PARA USARLA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98126507P | 2007-10-19 | 2007-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8800401A1 true PA8800401A1 (es) | 2009-05-15 |
Family
ID=40174735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20088800401A PA8800401A1 (es) | 2007-10-19 | 2008-10-17 | Productos quimioterapeuticos cristalinos |
Country Status (19)
Country | Link |
---|---|
US (1) | US7772404B2 (es) |
EP (1) | EP2195299A1 (es) |
JP (1) | JP2011500708A (es) |
KR (1) | KR20100084665A (es) |
CN (1) | CN101827825B (es) |
AU (1) | AU2008312534A1 (es) |
BR (1) | BRPI0818337A2 (es) |
CA (1) | CA2699356A1 (es) |
CO (1) | CO6270221A2 (es) |
CR (1) | CR11444A (es) |
DO (1) | DOP2010000111A (es) |
EC (1) | ECSP10010175A (es) |
GT (1) | GT201000099A (es) |
MX (1) | MX2010004287A (es) |
PA (1) | PA8800401A1 (es) |
RU (1) | RU2010119920A (es) |
UA (1) | UA99490C2 (es) |
WO (1) | WO2009052231A1 (es) |
ZA (1) | ZA201002094B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
JP2017524034A (ja) | 2014-08-08 | 2017-08-24 | フォーサイト・ビジョン フォー・インコーポレーテッドForsight Vision4, Inc. | 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
JP4810427B2 (ja) * | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
US20100105031A1 (en) * | 2005-08-01 | 2010-04-29 | Esai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
JP4989476B2 (ja) * | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
JP2009521493A (ja) * | 2005-12-23 | 2009-06-04 | アルコン,インコーポレイテッド | 眼への受容体チロシンキナーゼ阻害(RTKi)化合物の送達のための医薬製剤 |
EP2089003A1 (en) * | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
-
2008
- 2008-10-15 US US12/251,918 patent/US7772404B2/en not_active Expired - Fee Related
- 2008-10-16 CA CA2699356A patent/CA2699356A1/en not_active Abandoned
- 2008-10-16 JP JP2010530094A patent/JP2011500708A/ja active Pending
- 2008-10-16 UA UAA201006031A patent/UA99490C2/ru unknown
- 2008-10-16 EP EP08839994A patent/EP2195299A1/en not_active Withdrawn
- 2008-10-16 WO PCT/US2008/080068 patent/WO2009052231A1/en active Application Filing
- 2008-10-16 AU AU2008312534A patent/AU2008312534A1/en not_active Abandoned
- 2008-10-16 MX MX2010004287A patent/MX2010004287A/es active IP Right Grant
- 2008-10-16 CN CN2008801119519A patent/CN101827825B/zh not_active Expired - Fee Related
- 2008-10-16 KR KR1020107011003A patent/KR20100084665A/ko not_active Application Discontinuation
- 2008-10-16 BR BRPI0818337A patent/BRPI0818337A2/pt not_active IP Right Cessation
- 2008-10-16 RU RU2010119920/04A patent/RU2010119920A/ru not_active Application Discontinuation
- 2008-10-17 PA PA20088800401A patent/PA8800401A1/es unknown
-
2010
- 2010-03-24 ZA ZA2010/02094A patent/ZA201002094B/en unknown
- 2010-04-16 GT GT201000099A patent/GT201000099A/es unknown
- 2010-04-16 DO DO2010000111A patent/DOP2010000111A/es unknown
- 2010-04-27 CO CO10049269A patent/CO6270221A2/es not_active Application Discontinuation
- 2010-05-14 EC EC2010010175A patent/ECSP10010175A/es unknown
- 2010-05-19 CR CR11444A patent/CR11444A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA201002094B (en) | 2011-11-30 |
WO2009052231A1 (en) | 2009-04-23 |
CR11444A (es) | 2010-10-05 |
UA99490C2 (en) | 2012-08-27 |
BRPI0818337A2 (pt) | 2017-05-23 |
KR20100084665A (ko) | 2010-07-27 |
JP2011500708A (ja) | 2011-01-06 |
CA2699356A1 (en) | 2009-04-23 |
EP2195299A1 (en) | 2010-06-16 |
DOP2010000111A (es) | 2010-07-15 |
US7772404B2 (en) | 2010-08-10 |
CN101827825A (zh) | 2010-09-08 |
GT201000099A (es) | 2012-03-26 |
MX2010004287A (es) | 2010-04-30 |
CN101827825B (zh) | 2012-11-21 |
AU2008312534A1 (en) | 2009-04-23 |
ECSP10010175A (es) | 2010-06-29 |
CO6270221A2 (es) | 2011-04-20 |
RU2010119920A (ru) | 2011-11-27 |
US20090124816A1 (en) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121017T1 (el) | Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης | |
CY1115180T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
EA200802208A1 (ru) | Применение флибансерина для лечения расстройств полового влечения в постклимактерический период | |
EA200801138A1 (ru) | Применение флибансерина для лечения расстройств полового влечения в предклимактерический период | |
UY29777A1 (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión. | |
MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
ECSP10010145A (es) | Uso de 3,11b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria | |
GT200900319A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea | |
ECSP10010576A (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
PA8800401A1 (es) | Productos quimioterapeuticos cristalinos | |
CR11368A (es) | Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida | |
ECSP10010176A (es) | Productos quimioterapéuticos cristalinos | |
ECSP077843A (es) | Tratamiento o prevención del prurito | |
AR038698A1 (es) | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea | |
DOP2010000113A (es) | Productos quimioterapeuticos cristalinos | |
CL2008003709A1 (es) | Uso de 4-[2-(4-metilfenil-sulfanil)fenil]piperidina y sus sales, para tratar una enfermedad seleccionada de retardo psicomotriz, depresion grave, ansiedad, enfermedad de parkinson, epilepsia, entre otras. | |
CR9074A (es) | Agente para la profilaxis o tratamiento del sindrome metabolico | |
UY31407A1 (es) | "productos quimioterapéuticos cristalinos" | |
SV2006002017A (es) | Piperazinas derivadas de urea | |
ECSP11011212A (es) | Nueva asociación de ingredientes activos que contienen un fármaco antiinflamatorio, no esteroideo y un derivado de colchicósido | |
AR066108A1 (es) | Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson | |
BRPI0410704A (pt) | uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete | |
CL2008003551A1 (es) | Uso de fosfato y fumarato de propionato de 3-(2,2,2-trimetilhidrazinio) en la preparacion de medicamentos utiles en la profilaxis y el tratamiento de aterosclerosis. | |
UY31988A (es) | Compuestos de pirimidinilsulfonamida para utilizar en el tratamiento de una enfermedad mediada por quimiocina | |
UY28771A1 (es) | Piperazinas derivadas de úrea para el tratamiento de la endometrosis. |